Deucravacitinib outperformed placebo for treating moderate to severe scalp psoriasis, even among patients with less extensive overall disease.

Vaccination of 27- to 45-year-olds against HPV is less cost-effective than vaccination of younger persons (aged 9 to 26 years).

COVID-19, influenza, and RSV vaccination coverage is low among nursing home residents early in the 2024 to 2025 season.

Poor control over specific aspects of work is associated with burnout among physicians, according to study findings.

Baricitinib is an effective treatment option for children and adolescents with atopic dermatitis, with no new safety signals identified.

Tumor characteristics differ significantly among pediatric and adolescent and young AYA patients with melanoma, with decreasing incidence rates seen among young patients with cutaneous melanoma.

Preterm infants have thicker superficial components and more stepped borders for infantile hemangioma when compared with term infants.

The popularity of health apps raises significant issues in terms of patient privacy. HIPAA rules apply when protected (PHI) ...

No new safety concerns were observed through 16 weeks among pediatric patients with juvenile psoriatic arthritis or enthesitis-related arthritis receiving ixekizumab. Ixekizumab (IXE) demonstrated ...

To run the U.S. Centers for Disease Control and Prevention, Trump has turned to David Weldon, M.D., a long-time internist who interrupted his medical career to represent a Florida district for seven ...

Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).

Seasonal maternal respiratory syncytial virus vaccination and nirsevimab for infants demonstrate cost-effectiveness.